4//SEC Filing
LAINOVIC SACHA 4
Accession 0000899243-23-000999
CIK 0001720725other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 4:30 PM ET
Size
13.6 KB
Accession
0000899243-23-000999
Insider Transaction Report
Form 4
LAINOVIC SACHA
Director10% Owner
Transactions
- Disposition from Tender
Common Stock, par value $0.001 per share
2023-01-03−917,768→ 0 total(indirect: See Footnotes) - Disposition from Tender
Common Stock, par value $0.001 per share
2023-01-03−1,850,818→ 0 total(indirect: See Footnotes)
InvOpps GP IV, L.L.C.
Director10% Owner
Transactions
- Disposition from Tender
Common Stock, par value $0.001 per share
2023-01-03−917,768→ 0 total(indirect: See Footnotes) - Disposition from Tender
Common Stock, par value $0.001 per share
2023-01-03−1,850,818→ 0 total(indirect: See Footnotes)
InvOpps IV US, L.P.
Director10% Owner
Transactions
- Disposition from Tender
Common Stock, par value $0.001 per share
2023-01-03−1,850,818→ 0 total(indirect: See Footnotes) - Disposition from Tender
Common Stock, par value $0.001 per share
2023-01-03−917,768→ 0 total(indirect: See Footnotes)
InvOpps IV, L.P.
Director10% Owner
Transactions
- Disposition from Tender
Common Stock, par value $0.001 per share
2023-01-03−917,768→ 0 total(indirect: See Footnotes) - Disposition from Tender
Common Stock, par value $0.001 per share
2023-01-03−1,850,818→ 0 total(indirect: See Footnotes)
Footnotes (5)
- [F1]Pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement") by and among Viatris Inc. ("Viatris") and Viatris's wholly owned subsidiary, Iris Purchaser Inc. dated as of November 7, 2022, these shares of common stock, par value $0.001 per share were tendered prior to the Offer Expiration Time (as defined in the Merger Agreement) and disposed of at the Effective Time (as defined in the Merger Agreement) in exchange for the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent.
- [F2]Reflects securities directly held by InvOpps IV US, L.P. ("Invus IV US").
- [F3]Reflects securities directly held by InvOpps IV, L.P. ("Invus IV").
- [F4]InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP.
- [F5]Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Documents
Issuer
Oyster Point Pharma, Inc.
CIK 0001720725
Entity typeother
Related Parties
1- filerCIK 0001053891
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 4:30 PM ET
- Size
- 13.6 KB